Raising Capital Today, Part 2 - SPAC/IPO Paths to Public Markets

4:00 PM - 4:45 PM (EDT), Monday, June 14, 2021
Search General Info
Search Education
Search Partnering Companies

With a 175% increase in announced SPAC M&As for biopharma deals between 2019 and 2020, it’s clear that SPACs are an alternative financing option when compared to the more traditional IPOs. This session will outline the decision tree that private company CEOs, boards, and management teams must consider for making and timing the decision to transition from private to public ownership status.  Experts will use their real-world deal experiences to describe how to weigh the relative advantages and disadvantages of SPAC and IPO paths to raising capital, what can we expect to see in SPAC activity as the economy recovers post-pandemic, and why are SPACs back as a viable option after almost two decades.

Americas Leader for Life Sciences
Ernst & Young, LLP